ClinicalTrials.gov
public full text
Public Domain
Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months#995588
- Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes#1058188
- Risedronate in the Prevention of Osteoporosis in Postmenopausal Women#859384
- Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis#912106
- Effects of Exercise and Traditional Chinese Medical Modalities on Bone Structure and Function#1026183
Record · ID 967556
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive